373 related articles for article (PubMed ID: 30412238)
41. Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results.
Caramaschi P; Ruzzenente O; Pieropan S; Volpe A; Carletto A; Bambara LM; Biasi D
Rheumatol Int; 2007 May; 27(7):649-54. PubMed ID: 17136355
[TBL] [Abstract][Full Text] [Related]
42. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
43. Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment.
Chen DY; Chen YM; Hung WT; Chen HH; Hsieh CW; Chen YH; Huang WN; Hsieh TY
Ann Rheum Dis; 2015 Dec; 74(12):2261-4. PubMed ID: 26443609
[No Abstract] [Full Text] [Related]
44. Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Krüger K; Burmester GR; Wassenberg S; Thomas MH
Curr Med Res Opin; 2020 Sep; 36(9):1559-1567. PubMed ID: 32609555
[TBL] [Abstract][Full Text] [Related]
45. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
46. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
47. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.
Hernandez MV; Sanchez-Piedra C; Garcia-Magallon B; Cuende E; Manero J; Campos-Fernandez C; Martin-Domenech R; Del Pino-Montes J; Manrique S; Castro-Villegas MC; Ruiz-Montesinos D; Sanchez-Alonso F; Diaz-Gonzalez F; Cea-Calvo L; Gómez-Reino JJ;
Rheumatol Int; 2019 Mar; 39(3):509-515. PubMed ID: 30353269
[TBL] [Abstract][Full Text] [Related]
48. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
Deodhar A; Braun J; Inman RD; van der Heijde D; Zhou Y; Xu S; Han C; Hsu B
Ann Rheum Dis; 2015 Apr; 74(4):757-61. PubMed ID: 25387477
[TBL] [Abstract][Full Text] [Related]
49. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
Thomas K; Flouri I; Repa A; Fragiadaki K; Sfikakis PP; Koutsianas C; Kaltsonoudis E; Voulgari PV; Drosos AA; Petrikkou E; Sidiropoulos P; Vassilopoulos D
Clin Exp Rheumatol; 2018; 36(2):254-262. PubMed ID: 29148406
[TBL] [Abstract][Full Text] [Related]
50. Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.
Ziyadeh NJ; Geldhof A; Noël W; Otero-Lobato M; Esslinger S; Chakravarty SD; Wang Y; Seeger JD
Clin Drug Investig; 2020 Nov; 40(11):1021-1040. PubMed ID: 32779120
[TBL] [Abstract][Full Text] [Related]
51. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Bonovas S; Minozzi S; Lytras T; González-Lorenzo M; Pecoraro V; Colombo S; Polloni I; Moja L; Cinquini M; Marino V; Goletti D; Matucci A; Tocci G; Milano GM; Scarpa R; Cantini F
Expert Opin Drug Saf; 2016 Dec; 15(sup1):35-54. PubMed ID: 27924644
[TBL] [Abstract][Full Text] [Related]
52. Dermatologic adverse events: golimumab, friend or foe?
Zidi I; Bartegi A; Ben AN
Pharmazie; 2011 Jan; 66(1):5-10. PubMed ID: 21391428
[TBL] [Abstract][Full Text] [Related]
53. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
54. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
[TBL] [Abstract][Full Text] [Related]
55. Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis.
Immonen K; Kauppi M; Hakala M
Scand J Rheumatol; 2011 May; 40(3):236-8. PubMed ID: 21231814
[No Abstract] [Full Text] [Related]
56. Golimumab.
Pappas DA; Bathon JM; Hanicq D; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2009 Sep; 8(9):695-6. PubMed ID: 19721444
[No Abstract] [Full Text] [Related]
57. Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies.
Hutas G
Immunotherapy; 2010 Jul; 2(4):453-60. PubMed ID: 20635999
[TBL] [Abstract][Full Text] [Related]
58. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
[TBL] [Abstract][Full Text] [Related]
59. Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.
Wasko MC; Hsia EC; Kirkham B; Touboul PJ; Fleischmann R; Genovese MC; Matteson EL; Lu J; Xu W; Rahman MU
J Clin Rheumatol; 2014 Jan; 20(1):1-10. PubMed ID: 24356481
[TBL] [Abstract][Full Text] [Related]
60. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
